|September 28, 2012|
|06:01 EDT||ACTG, BSX||Acacia Research unit enters into settlement agreement with Boston Scientific |
Acacia Research Corporation (ACTG) announced that its Body Science LLC subsidiary has entered into a settlement agreement with Boston Scientific Corporation (BSX). The agreement resolves litigation that was pending in the United States District Court for the District of Minnesota.
News For ACTG;BSX From The Last 14 Days
|April 24, 2015|
|10:11 EDT||ACTG||High option volume stocks|
High option volume stocks: AERI UEC NUAN DSW CHU SVU PII ACTG GIMO JNPR
|April 23, 2015|
|16:09 EDT||ACTG||Acacia Research announces approval of quarterly dividend|
Subscribe for More Information
|16:07 EDT||ACTG||Acacia Research reports Q1 EPS 6c, consensus 5c|
Subscribe for More Information
|06:25 EDT||ACTG||Acacia Research subsidiaries enters into settlement agreement with Amazon|
Saint Lawrence Communications LLC and Saint Lawrence Communications GMBH, subsidiaries of Acacia Research (ACTG), entered into a settlement and license agreement with Amazon (AMZN).
|April 20, 2015|
|16:09 EDT||BSX||Boston Scientific announces long-term data underscore safety, efficacy of S-ICD|
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
|07:44 EDT||BSX||Survey shows strong momentum for Boston Scientific devices, says RBC Capital|
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.
|April 16, 2015|
|16:11 EDT||BSX||Boston Scientific enrolls first patient REDUCE-HTN: REINFORCE study|
Boston Scientific announced the first patient in the REDUCE-HTN: REINFORCE study was enrolled this week at Cardiology P.C. at Princeton Baptist Medical Center in Birmingham, AL by Farrell Mendelsohn, M.D., site principal investigator, and referred by Michael Wilensky, M.D. Boston Scientific received an investigational device exemption, or IDE, for the study from the FDA in December.
|April 14, 2015|
|09:09 EDT||BSX||Boston Scientific announces strategic alliance with Frankenman|
Boston Scientific announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader with deep local market expertise in the China surgical devices market. This alliance is expected to enable Boston Scientific and Frankenman to reach more clinicians and treat more patients by providing access to training on less invasive endoscopic technologies and the clinical and economic benefits these therapies can provide. CPEChina Fund, an entity of CITIC PE, is a current shareholder of Frankenman and will continue to support the company's growth in alignment with this strategic partnership.Under the terms of the agreement, Boston Scientific will become a shareholder of Frankenman, and provide services and expertise to Frankenman to support its continued growth, development pipeline and manufacturing capabilities. The transaction is expected to close in the first half of 2015, subject to customary closing conditions.